Diclegis was pulled from the U.S. market in 1983 — not because regulators found it dangerous, but because the company that made its predecessor, Bendectin, could no longer afford the avalanche of lawsuits claiming it caused birth defects. Thirty years later, the FDA approved Diclegis with the exact same active ingredients and its highest pregnancy safety rating, effectively confirming what the scientific evidence had shown all along: the drug never should have disappeared in the first place. The story of Diclegis is one of the starkest examples in modern pharmaceutical history of how litigation, not science, can dictate which medications reach patients.
For readers of this site focused on brain health and dementia care, the Diclegis saga carries particular relevance. It illustrates how fear-driven decision-making around medications can have cascading public health consequences — a pattern that repeats across neurological and psychiatric prescribing. After Bendectin was pulled, hospitalizations for severe pregnancy nausea and vomiting doubled, leaving pregnant women without a proven treatment for years. This article covers the full arc: what Bendectin was, why it was withdrawn, the real-world harm that followed, how the drug returned as Diclegis, questions about its efficacy, and what patients face today in terms of cost and access.
Table of Contents
- Why Was the Morning Sickness Drug Bendectin Pulled From the Market?
- The Public Health Fallout When a Safe Drug Disappears
- How Diclegis Returned to the Market in 2013
- Efficacy Questions and What the Unpublished Data Showed
- The Cost Problem and the Generic Alternative
- Lessons for Medication Policy and Vulnerable Populations
- Where Diclegis Stands Today
- Conclusion
- Frequently Asked Questions
Why Was the Morning Sickness Drug Bendectin Pulled From the Market?
Bendectin was approved in 1956 as a three-ingredient combination of dicyclomine, doxylamine succinate, and pyridoxine (vitamin B6) for treating nausea and vomiting during pregnancy. At its peak, roughly one in four pregnant women in the United States took the drug. In 1976, the FDA approved a streamlined two-drug version after dicyclomine was found to be ineffective for pregnancy nausea, leaving doxylamine and pyridoxine as the active formula. In the late 1970s, lawsuits began alleging that Bendectin caused birth defects. Hundreds of cases were filed against manufacturer Merrell Dow Pharmaceuticals, and the legal costs mounted rapidly. By 1983, Merrell Dow made a business decision: it voluntarily withdrew Bendectin from the U.S. market.
The FDA had not ordered it removed. The agency had not found safety problems. The drug was pulled because skyrocketing litigation and insurance costs made it unprofitable to sell. Multiple meta-analyses conducted before and after the withdrawal found no evidence that Bendectin increased birth defect risk above the baseline rate of approximately 1 in 33 babies — a rate that exists regardless of any medication exposure. The Bendectin episode became a landmark case in tort law, eventually reaching the U.S. Supreme Court in Daubert v. Merrell Dow Pharmaceuticals, which reshaped how courts evaluate scientific expert testimony. But for the pregnant women who lost access to an effective treatment, the legal precedent was cold comfort.
The Public Health Fallout When a Safe Drug Disappears
The consequences of Bendectin’s withdrawal were measurable and severe. According to National Center for Health Statistics data cited in the New England Journal of Medicine, hospitalizations for pregnancy-related nausea and vomiting doubled — from 7 per 1,000 live births during 1974–1980 to 15–16 per 1,000 live births between 1981 and 1987. women who would have managed their symptoms with a proven oral medication were instead ending up in emergency departments for intravenous hydration and extended hospital stays. This pattern is worth examining for anyone who follows medication policy and brain health.
When effective treatments are removed from the market due to non-scientific pressures, vulnerable populations bear the cost. The same dynamic plays out in neuropsychiatric medicine, where stigma and litigation fears can restrict access to medications for conditions like epilepsy, depression, and dementia-related behavioral symptoms. However, if a drug truly does carry safety risks, withdrawal is appropriate — the critical distinction with Bendectin is that the scientific evidence consistently supported its safety, and the withdrawal was driven entirely by legal and financial pressures. For nearly three decades, no FDA-approved drug existed specifically for nausea and vomiting of pregnancy. Physicians improvised with off-label prescriptions of the same ingredients — over-the-counter doxylamine (sold as Unisom SleepTabs) combined with vitamin B6 — but without standardized dosing, delayed-release formulation, or formal regulatory oversight of the combination.
How Diclegis Returned to the Market in 2013
On April 8, 2013, the FDA approved Diclegis, manufactured by the Canadian company Duchesnay USA. The formulation — doxylamine 10mg combined with pyridoxine 10mg in a delayed-release tablet — contained the same active ingredients as the reformulated Bendectin that had been pulled thirty years earlier. The FDA granted Diclegis a Pregnancy Category A designation, the highest safety rating available, reserved for drugs with well-controlled human studies showing no fetal risk. Diclegis became the only FDA-approved medication specifically indicated for nausea and vomiting of pregnancy.
The approval was based on decades of accumulated safety data covering millions of exposures, plus a new randomized controlled trial. For the medical community, the approval was a vindication — a formal acknowledgment that the original withdrawal had been a failure of the legal system, not a failure of the drug. For patients, it meant a return to having an FDA-sanctioned option with clear dosing instructions and pharmacy availability, rather than relying on jury-rigged combinations of over-the-counter sleep aids and vitamin supplements. Duchesnay also developed Bonjesta, a higher-dose extended-release formulation containing 20mg doxylamine and 20mg pyridoxine, aimed at women who needed stronger symptom control with fewer daily tablets. Both products addressed the same condition, but Bonjesta’s extended-release design allowed for twice-daily rather than multiple-times-daily dosing.
Efficacy Questions and What the Unpublished Data Showed
In January 2017, University of Toronto researchers published a paper in PLoS One that introduced new uncertainty into the Diclegis story. They had obtained previously unpublished data from 1970s-era Bendectin clinical trials and raised questions about whether the drug was actually more effective than placebo. The findings did not suggest the drug was unsafe — the safety profile remained well-supported — but they challenged the strength of the evidence that it worked better than doing nothing. This is a meaningful distinction. A drug can be safe without being particularly effective, and that tradeoff matters when patients are paying hundreds of dollars for a brand-name prescription.
However, the published 2013 clinical trial that supported the FDA approval did show a statistically significant improvement in nausea and vomiting scores compared to placebo. The debate, then, is not black-and-white but rather about how large the benefit is and whether it justifies the cost — particularly the brand-name cost. For some women, even a modest reduction in nausea during pregnancy represents a significant quality-of-life improvement, while others may find equal relief from the over-the-counter ingredients at a fraction of the price. Clinicians weighing Diclegis for patients should consider the individual severity of symptoms. For mild nausea, the combination of OTC doxylamine and vitamin B6 — which is what Diclegis contains — may be a reasonable and far cheaper starting point. For moderate to severe cases, the delayed-release formulation of Diclegis or Bonjesta may offer better symptom control through more consistent drug levels.
The Cost Problem and the Generic Alternative
One of the most persistent criticisms of Diclegis has been its price. As of 2026, brand-name Diclegis retails at approximately $432 for 60 tablets without insurance. Given that the active ingredients — doxylamine and pyridoxine — have been available over the counter for decades, this pricing has drawn scrutiny from patients, physicians, and pharmacists alike. Generic doxylamine-pyridoxine delayed-release tablets are now available for roughly $45–50 for 60 tablets through discount pharmacy programs, representing savings of nearly 90% over the brand name.
Mark Cuban’s Cost Plus Drugs also carries the generic version, further expanding access for uninsured or underinsured patients. For families already navigating the financial pressures of pregnancy or managing costs for an aging parent with dementia in the household, the difference between $432 and $45 is not trivial. The warning here is straightforward: if a pharmacy dispenses the brand name when a generic is available, the out-of-pocket cost can be dramatically higher. Patients should specifically ask for the generic doxylamine-pyridoxine combination and confirm pricing before filling the prescription. Insurance coverage varies widely, and some plans may cover the brand while others only cover the generic — or neither.
Lessons for Medication Policy and Vulnerable Populations
The Diclegis story offers a case study in how non-medical forces shape medication access. Pregnant women went without a proven treatment for thirty years because a pharmaceutical company decided the legal risk outweighed the revenue. No regulatory body made the call to remove the drug.
No new safety data emerged to justify it. A manufacturer’s cost-benefit calculation, driven by a litigation environment that did not align with the scientific evidence, left an entire patient population underserved. This pattern echoes in dementia care, where off-label prescribing of antipsychotics, the slow pace of new drug approvals, and liability concerns all influence what treatments are available and how freely clinicians feel they can prescribe them. The takeaway is not that all medications are safe or that lawsuits are always unfounded — it is that the system for evaluating and distributing medications can be distorted by forces that have nothing to do with patient welfare.
Where Diclegis Stands Today
As of 2026, no major new lawsuits or regulatory actions have targeted Diclegis. The drug remains the only FDA-approved treatment specifically for nausea and vomiting of pregnancy, and the availability of affordable generic versions has improved access considerably since the brand’s initial approval.
The underlying safety data, accumulated over more than six decades and millions of exposures, continues to support its use. Looking ahead, the Diclegis story may serve as a reference point as the pharmaceutical industry and regulators grapple with similar dynamics in other therapeutic areas — including Alzheimer’s treatments, where high costs, contested efficacy data, and intense public scrutiny create familiar tensions. The question of how society handles the gap between scientific evidence and public fear remains as relevant as ever.
Conclusion
Diclegis was never pulled because it was dangerous. Its predecessor, Bendectin, was withdrawn in 1983 because the cost of defending against hundreds of birth defect lawsuits — lawsuits that the scientific evidence did not support — made the drug unprofitable. The consequences were real and measurable: hospitalizations for severe pregnancy nausea doubled in the years that followed.
When the FDA approved Diclegis in 2013 with the same active ingredients and its highest pregnancy safety rating, it effectively corrected a three-decade-long market failure driven by litigation rather than science. For patients and caregivers navigating the healthcare system — whether dealing with pregnancy nausea or managing medications for a loved one with dementia — the Diclegis saga is a reminder to look past headlines and examine the actual evidence behind medication decisions. Generic doxylamine-pyridoxine is now available at a fraction of the brand-name cost, and the drug’s safety profile is among the most thoroughly studied in obstetric medicine. When fear, not data, drives treatment decisions, patients pay the price.
Frequently Asked Questions
Is Diclegis the same drug as Bendectin?
Diclegis contains the same two active ingredients — doxylamine succinate and pyridoxine (vitamin B6) — as the reformulated version of Bendectin that was sold from 1976 until its withdrawal in 1983. The delayed-release tablet formulation is designed to provide consistent drug levels, but the active medication is identical.
Why was Bendectin taken off the market if it was safe?
Manufacturer Merrell Dow voluntarily withdrew Bendectin in 1983 because the cost of defending against hundreds of lawsuits alleging birth defects made the drug unprofitable. The FDA did not order its removal, and multiple scientific meta-analyses found no evidence that the drug increased birth defect risk above the baseline rate of approximately 1 in 33 pregnancies.
How much does Diclegis cost without insurance?
Brand-name Diclegis retails at approximately $432 for 60 tablets as of 2026. Generic doxylamine-pyridoxine is available for roughly $45–50 for 60 tablets through discount programs, including Mark Cuban’s Cost Plus Drugs.
Is Diclegis safe during pregnancy?
The FDA gave Diclegis its highest pregnancy safety designation (Category A), meaning well-controlled human studies showed no fetal risk. The drug’s safety has been studied across millions of exposures over more than sixty years.
What is the difference between Diclegis and Bonjesta?
Bonjesta is a higher-dose formulation by the same manufacturer, containing 20mg each of doxylamine and pyridoxine in an extended-release tablet, compared to Diclegis’s 10mg/10mg delayed-release formulation. Bonjesta allows for less frequent dosing but delivers a larger dose per tablet.
Did the 2017 efficacy study prove Diclegis doesn’t work?
The 2017 University of Toronto study raised questions about the strength of older efficacy data but did not prove the drug is ineffective. The 2013 clinical trial supporting FDA approval did show statistically significant improvement in nausea and vomiting scores compared to placebo. The debate is about how large the benefit is, not whether the drug is safe.
